Merial Limited

Boehringer Ingelheim Animal Health USA Inc.

Sanofi Pasteur Sa

Sanofi Pasteur Inc.

François-Xavier Le Gros

Michel Joseph Bublot

Frederic Reynard

Jacqueline Elizabeth Shea

Sylvain Gabriel Goutebroze

Helen Rachel Crooke

Robert Graham Feldman

Isabelle Legastelois

Catherine Moste

Catherine Gerdil

Michel Joseph Marie Bublot

Stephane Lemiere

The present invention encompasses engineered Newcastle Disease Virus (NDV) vaccines or compositions. The vaccine or composition may be a recombinant vaccine. The invention also encompasses recombinant vectors encoding and expressing avian pathogen antigens, more specifically avian influenza proteins, epitopes or immunogens. Such vaccines or compositions can be used to protect animals, in particular avian, against disease.

Newcastle disease virus vectored avian vaccines

The present invention relates to the field of vaccination againstin animals, particularly avian animals. The present invention also encompasses kits and uses ofimmunogenic compositions or vaccines. The present invention further relates to methods and compositions comprising at least one primo-administration of an attenuated immunogenic composition or vaccine, comprising a pharmaceutically or veterinarily acceptable excipient, diluent or vehicle and at least one attenuated, administered to an avian animal before at least one boost-administration of an inactivated immunogenic composition or vaccine, comprising a pharmaceutically or veterinarily acceptable excipient, diluent or vehicle, and at least one inactivated

[object Object]

Disclosed and claimed are a mutant of a gram negative bacterium, wherein said bacterium has at least one mutation in a nucleotide sequence which codes for a polypeptide having an identity which is equal or more than 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% with an amino acid sequence coded by a nucleotide sequence selected from the group consisting of nucleotide sequences identified SEQ ID NO: 2, 6, 9, 12, 16, 19, 22, 25, 28, 31, 34, 37, 40, 43, 46, 49, 52, 55, 58, 61, 64, 67, 70, 75, 78, 81, 84, 87, 90, 93; said mutation resulting in attenuated virulence of the bacterium. Immunogenic compositions and vaccines containing such a mutant are also disclosed and claimed.

Attenuated gram negative bacteria

The invention relates to a method for producing flu virus according to which:

Method for producing the flu virus

Growing community of inventors

Saint Genis Laval, France

François-Xavier Le Gros